A clinical study of 77 patients with mucopolysaccharidosis type II
about
CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)Birth weight in patients with mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS).Hunter Syndrome with Extensive Mongolian Spots.Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years.Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment.Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey.[Efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II with and without comparison to placebo: systematic review and meta-analysis].Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and managementDeep Genotyping of the IDS Gene in Colombian Patients with Hunter Syndrome.A patient presenting a 22q13 deletion associated with an apparently balanced translocation t(16;22): An illustrative case in the investigation of patients with low ARSA activityEnzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients.A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS IIMucopolysaccharidosis Type II and the G374sp Mutation.Detection by Urinary GAG Testing of Mucopolysaccharidosis Type II in an At-Risk Spanish Population.Management of otolaryngological manifestations in mucopolysaccharidoses: our experience.Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed.Review of the use of idursulfase in the treatment of mucopolysaccharidosis II.The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II.Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II - Hunter syndrome.Impact of enzyme replacement therapy on linear growth in Korean patients with mucopolysaccharidosis type II (Hunter syndrome).Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders.Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.Management of the behavioural manifestations of Hunter syndrome.Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II.Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS).Clinical and biochemical study of 29 Brazilian patients with metachromatic leukodystrophy.Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II.Initial report from the Hunter Outcome Survey.Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).Heparin cofactor II thrombin complex as a biomarker for mucopolysaccharidosis: Indian experience.Health-Related Quality of Life in Patients with MPS II.Perturbations in cell signaling elicit early cardiac defects in mucopolysaccharidosis type II.Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II.Growth patterns in children with mucopolysaccharidosis I and II.Quality of life in mucopolysaccharidoses: construction of a specific measure using the focus group technique.Non-convulsive status epilepticus of frontal origin in mucopolysaccharidosis type II successfully treated with ethosuximide.Hunter syndrome in an 11-year old girl on enzyme replacement therapy with idursulfase: brain magnetic resonance imaging features and evolution.Cognitive and behaviour profiles of children with mucopolysaccharidosis Type II.Oral and craniofacial manifestations in a Hunter syndrome patient with hematopoietic stem cell transplantation: A case report.
P2860
Q27333793-D2C13DB2-3630-44BF-86EE-5249B5C8B861Q33660434-71FC295C-94DA-4452-85B0-85C0F2E1E4E2Q33710704-36F4F9F4-4A6E-4C77-AE2D-FCC0AA109EA6Q34266971-8916D8E5-298F-44A6-BEC3-CACCBAABB314Q34562817-334B5184-0EFE-42A9-9FBD-EE9CCA7E3409Q35128899-C961EB56-DBC0-4C73-BFC0-BB06AC3BE58CQ35427537-0D58C325-AF0A-453D-82A0-A85F38E883EEQ35571515-6A0A5B66-BD76-4D78-8D18-5835191A6D43Q35587435-22C90596-EEBD-4D71-90B1-B35C9E074EC2Q35848742-D47E23B4-AADA-427F-B2C4-5151867CFE61Q36075589-21708C14-D7AA-482A-8FBC-D2ED3C55DC63Q36571573-B2E87307-1264-448B-8B53-5EE43082B919Q36799227-50785C04-02BF-4BDD-908A-180E748C7F7AQ36883369-4D8F4BEE-FE67-4E55-BBC9-2215F3252A19Q37127684-881572C0-2A92-461D-B1CC-180530552464Q37173777-43DCF215-3E93-4745-9E60-810E8F2CE80FQ37212850-A5106C44-F49F-48BB-951E-F2EE8204E024Q37290634-FCD390EF-35C9-4093-A9BC-40F3BDC88FCFQ37472945-AAB0D8D9-F63D-4776-9BC0-D323562620E8Q37579048-57D2E235-1B70-4DC2-8620-666792D14E90Q37583057-C77F299C-1191-4EF8-9918-E9E4B194A44EQ38079401-A7533B65-052D-4508-BEEA-477D61A900C2Q38634722-2591F3DE-7F9F-49D2-93B9-7B6CA0D32CC5Q38696810-C167C38A-1113-49D7-97FA-E79F41B972BAQ39094272-18E5D530-72CB-4295-BB83-03B18932065DQ40049935-AD48E80C-B7F5-487B-AE32-38ED293B1F5FQ42473685-3C7A2D77-D667-4816-956F-B43E55C03AE3Q42579881-B52E850C-9305-4473-8E08-9CB36444E89FQ44328956-F07E015B-3523-46B3-83D1-275804DEFBE8Q45874778-983A51D1-A07A-4F6D-8C68-F2F30D9E1C7DQ45910448-9FAA6ECA-2EE3-410E-B069-6A21E109C0E8Q45962203-BDE44FBB-4D46-4FA9-8A25-5352CDC12F7DQ47073378-D7FAD4B7-A8A2-4C21-BE8A-838F9E938E42Q47351924-70BAB6F5-CE85-453F-B155-F429FD3CE7FBQ47587025-47877BC7-B7F0-470B-A0A9-883BFDB940F9Q48241333-298BCA17-1282-48CD-AFF2-4CD71098B0D4Q48254293-F946AF89-5FBB-4F6B-ABA7-E56582027D86Q48355069-DCE63D2B-2478-44E8-A1E6-FAAB1828EAF9Q50053343-3EAA238A-36E7-454E-B009-CDC0CD9C1450Q50124499-79881F13-47CD-4E22-A516-55EC5BD985BC
P2860
A clinical study of 77 patients with mucopolysaccharidosis type II
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A clinical study of 77 patients with mucopolysaccharidosis type II
@ast
A clinical study of 77 patients with mucopolysaccharidosis type II
@en
A clinical study of 77 patients with mucopolysaccharidosis type II
@nl
type
label
A clinical study of 77 patients with mucopolysaccharidosis type II
@ast
A clinical study of 77 patients with mucopolysaccharidosis type II
@en
A clinical study of 77 patients with mucopolysaccharidosis type II
@nl
prefLabel
A clinical study of 77 patients with mucopolysaccharidosis type II
@ast
A clinical study of 77 patients with mucopolysaccharidosis type II
@en
A clinical study of 77 patients with mucopolysaccharidosis type II
@nl
P2093
P3181
P1433
P1476
A clinical study of 77 patients with mucopolysaccharidosis type II
@en
P2093
Agnes C Fett-Conte
Andréa R Duarte
Anna Carolina Paula
Chong A Kim
Cyro D Martinhago
Dafne Horovitz
Denise Y J Norato
Emerson S Santos
Eugênia Valadares
Fernando Kok
P3181
P356
10.1111/J.1651-2227.2007.00212.X
P407
P577
2007-04-01T00:00:00Z